These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21246934)

  • 1. New directions in multiple sclerosis therapy: matching therapy with pathogenesis.
    Antel J
    Can J Neurol Sci; 2010 Sep; 37 Suppl 2():S42-8. PubMed ID: 21246934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis.
    Martin R; Sospedra M; Rosito M; Engelhardt B
    Eur J Immunol; 2016 Sep; 46(9):2078-90. PubMed ID: 27467894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligodendrocyte/myelin injury and repair as a function of the central nervous system environment.
    Antel J
    Clin Neurol Neurosurg; 2006 Mar; 108(3):245-9. PubMed ID: 16384636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the innate and adaptive immune responses in the course of multiple sclerosis.
    Hemmer B; Kerschensteiner M; Korn T
    Lancet Neurol; 2015 Apr; 14(4):406-19. PubMed ID: 25792099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis: etiological mechanisms and future directions.
    Lutton JD; Winston R; Rodman TC
    Exp Biol Med (Maywood); 2004 Jan; 229(1):12-20. PubMed ID: 14709772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy.
    Steinman L; Martin R; Bernard C; Conlon P; Oksenberg JR
    Annu Rev Neurosci; 2002; 25():491-505. PubMed ID: 12052918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of human glia by multiple sclerosis disease modifying therapies.
    Healy LM; Michell-Robinson MA; Antel JP
    Semin Immunopathol; 2015 Nov; 37(6):639-49. PubMed ID: 26259734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate immune responses in the CNS: role of toll-like receptors, mechanisms, and therapeutic opportunities in multiple sclerosis.
    Podda G; Nyirenda M; Crooks J; Gran B
    J Neuroimmune Pharmacol; 2013 Sep; 8(4):791-806. PubMed ID: 23812895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.
    Ziemssen T
    J Neurol; 2005 Nov; 252 Suppl 5():v38-45. PubMed ID: 16254701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approaches and cutting edge immunotherapies in multiple sclerosis.
    Bauman TM; Kasper LH
    Front Biosci; 2004 Sep; 9():2302-22. PubMed ID: 15353289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the immune pathogenesis and treatment of multiple sclerosis.
    Huang D; Rae-Grant A
    Cent Nerv Syst Agents Med Chem; 2009 Mar; 9(1):20-31. PubMed ID: 20021335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infections in MS: An innate immunity perspective.
    Hänninen A
    Acta Neurol Scand; 2017 Nov; 136 Suppl 201():10-14. PubMed ID: 29068495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New concepts in the immunopathogenesis of multiple sclerosis.
    Hemmer B; Archelos JJ; Hartung HP
    Nat Rev Neurosci; 2002 Apr; 3(4):291-301. PubMed ID: 11967559
    [No Abstract]   [Full Text] [Related]  

  • 14. The CNS as a therapeutic target in multiple sclerosis.
    Antel JP
    Curr Neurol Neurosci Rep; 2008 Nov; 8(6):445-7. PubMed ID: 18957179
    [No Abstract]   [Full Text] [Related]  

  • 15. Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.
    Singh V; Tripathi A; Dutta R
    Proteomics; 2019 Aug; 19(16):e1800335. PubMed ID: 31119864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple sclerosis and central nervous system demyelination.
    Pouly S; Antel JP
    J Autoimmun; 1999 Nov; 13(3):297-306. PubMed ID: 10550217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-level laser therapy ameliorates disease progression in a mouse model of multiple sclerosis.
    Gonçalves ED; Souza PS; Lieberknecht V; Fidelis GS; Barbosa RI; Silveira PC; de Pinho RA; Dutra RC
    Autoimmunity; 2016; 49(2):132-42. PubMed ID: 26703077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A minimal unified model of disease trajectories captures hallmarks of multiple sclerosis.
    Kannan V; Kiani NA; Piehl F; Tegner J
    Math Biosci; 2017 Jul; 289():1-8. PubMed ID: 28365299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central nervous system effects of current and emerging multiple sclerosis-directed immuno-therapies.
    Antel JP; Miron VE
    Clin Neurol Neurosurg; 2008 Nov; 110(9):951-7. PubMed ID: 18502570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired channelopathies as contributors to development and progression of multiple sclerosis.
    Schattling B; Eggert B; Friese MA
    Exp Neurol; 2014 Dec; 262 Pt A():28-36. PubMed ID: 24656770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.